Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

Posted by Stephan Jacobs on Feb 5th, 2025

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research note published on Sunday. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Down 22.0 %

NASDAQ TNXP opened at $0.15 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock’s 50-day simple moving average is $0.30 and its two-hundred day simple moving average is $0.27. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $12.48. The company has a market capitalization of $28.43 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Research analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.